These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 22766359)

  • 21. A twenty-eight-day mechanistic time course study in the rhesus monkey with hepatitis C virus protease inhibitor BILN 2061.
    Stoltz JH; Stern JO; Huang Q; Seidler RW; Pack FD; Knight BL
    Toxicol Pathol; 2011 Apr; 39(3):496-501. PubMed ID: 21441227
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sensitivity of NS3 serine proteases from hepatitis C virus genotypes 2 and 3 to the inhibitor BILN 2061.
    Thibeault D; Bousquet C; Gingras R; Lagacé L; Maurice R; White PW; Lamarre D
    J Virol; 2004 Jul; 78(14):7352-9. PubMed ID: 15220408
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ultra-rapid cardiotoxicity of the hepatitis C virus protease inhibitor BILN 2061 in the urokinase-type plasminogen activator mouse.
    Vanwolleghem T; Meuleman P; Libbrecht L; Roskams T; De Vos R; Leroux-Roels G
    Gastroenterology; 2007 Oct; 133(4):1144-55. PubMed ID: 17919490
    [TBL] [Abstract][Full Text] [Related]  

  • 24. "Strong reasons make strong actions"--The antiviral efficacy of NS3/4A protease inhibitors.
    Lemon SM; Yi M; Li K
    Hepatology; 2005 Mar; 41(3):671-4. PubMed ID: 15723328
    [No Abstract]   [Full Text] [Related]  

  • 25. Macrocyclic inhibitors of HCV NS3 protease.
    Venkatraman S; Njoroge FG
    Expert Opin Ther Pat; 2009 Sep; 19(9):1277-303. PubMed ID: 19563268
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Estimation of inhibitory quotient using a comparative equilibrium dialysis assay for prediction of viral response to hepatitis C virus inhibitors.
    Mo H; Yang C; Wang K; Wang Y; Huang M; Murray B; Qi X; Sun SC; Deshpande M; Rhodes G; Miller MD
    J Viral Hepat; 2011 May; 18(5):338-48. PubMed ID: 20456634
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design and synthesis of depeptidized macrocyclic inhibitors of hepatitis C NS3-4A protease using structure-based drug design.
    Venkatraman S; Njoroge FG; Girijavallabhan VM; Madison VS; Yao NH; Prongay AJ; Butkiewicz N; Pichardo J
    J Med Chem; 2005 Aug; 48(16):5088-91. PubMed ID: 16078825
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Binding of heparin to metals.
    Stevic I; Parmar N; Paredes N; Berry LR; Chan AK
    Cell Biochem Biophys; 2011 Apr; 59(3):171-8. PubMed ID: 20981507
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiviral interactions of an HCV polymerase inhibitor with an HCV protease inhibitor or interferon in vitro.
    Koev G; Dekhtyar T; Han L; Yan P; Ng TI; Lin CT; Mo H; Molla A
    Antiviral Res; 2007 Jan; 73(1):78-83. PubMed ID: 16945431
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Convergent synthesis of the quinolone substructure of BILN 2061 via carbonylative Sonogashira coupling/cyclization.
    Haddad N; Tan J; Farina V
    J Org Chem; 2006 Jun; 71(13):5031-4. PubMed ID: 16776542
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibitors of hepatitis C virus NS3.4A protease 2. Warhead SAR and optimization.
    Perni RB; Pitlik J; Britt SD; Court JJ; Courtney LF; Deininger DD; Farmer LJ; Gates CA; Harbeson SL; Levin RB; Lin C; Lin K; Moon YC; Luong YP; O'Malley ET; Rao BG; Thomson JA; Tung RD; Van Drie JH; Wei Y
    Bioorg Med Chem Lett; 2004 Mar; 14(6):1441-6. PubMed ID: 15006379
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A systematic approach to the optimization of substrate-based inhibitors of the hepatitis C virus NS3 protease: discovery of potent and specific tripeptide inhibitors.
    Llinàs-Brunet M; Bailey MD; Ghiro E; Gorys V; Halmos T; Poirier M; Rancourt J; Goudreau N
    J Med Chem; 2004 Dec; 47(26):6584-94. PubMed ID: 15588093
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel macrocyclic HCV NS3 protease inhibitors derived from α-amino cyclic boronates.
    Li X; Zhang YK; Liu Y; Ding CZ; Zhou Y; Li Q; Plattner JJ; Baker SJ; Zhang S; Kazmierski WM; Wright LL; Smith GK; Grimes RM; Crosby RM; Creech KL; Carballo LH; Slater MJ; Jarvest RL; Thommes P; Hubbard JA; Convery MA; Nassau PM; McDowell W; Skarzynski TJ; Qian X; Fan D; Liao L; Ni ZJ; Pennicott LE; Zou W; Wright J
    Bioorg Med Chem Lett; 2010 Oct; 20(19):5695-700. PubMed ID: 20801653
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Induced-fit binding of the macrocyclic noncovalent inhibitor TMC435 to its HCV NS3/NS4A protease target.
    Cummings MD; Lindberg J; Lin TI; de Kock H; Lenz O; Lilja E; Felländer S; Baraznenok V; Nyström S; Nilsson M; Vrang L; Edlund M; Rosenquist A; Samuelsson B; Raboisson P; Simmen K
    Angew Chem Int Ed Engl; 2010 Feb; 49(9):1652-5. PubMed ID: 20166108
    [No Abstract]   [Full Text] [Related]  

  • 35. Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection.
    Tsantrizos YS; Bolger G; Bonneau P; Cameron DR; Goudreau N; Kukolj G; LaPlante SR; Llinàs-Brunet M; Nar H; Lamarre D
    Angew Chem Int Ed Engl; 2003 Mar; 42(12):1356-60. PubMed ID: 12671967
    [No Abstract]   [Full Text] [Related]  

  • 36. Synthesis of bis-macrocyclic HCV protease inhibitor MK-6325 via intramolecular sp²-sp³ Suzuki-Miyaura coupling and ring closing metathesis.
    Li H; Scott JP; Chen CY; Journet M; Belyk K; Balsells J; Kosjek B; Baxter CA; Stewart GW; Wise C; Alam M; Song ZJ; Tan L
    Org Lett; 2015 Mar; 17(6):1533-6. PubMed ID: 25754231
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery and structure-activity relationship of P1-P3 ketoamide derived macrocyclic inhibitors of hepatitis C virus NS3 protease.
    Venkatraman S; Velazquez F; Wu W; Blackman M; Chen KX; Bogen S; Nair L; Tong X; Chase R; Hart A; Agrawal S; Pichardo J; Prongay A; Cheng KC; Girijavallabhan V; Piwinski J; Shih NY; Njoroge FG
    J Med Chem; 2009 Jan; 52(2):336-46. PubMed ID: 19102654
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatitis C virus resistance to protease inhibitors.
    Halfon P; Locarnini S
    J Hepatol; 2011 Jul; 55(1):192-206. PubMed ID: 21284949
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel robust hepatitis C virus mouse efficacy model.
    Zhu Q; Oei Y; Mendel DB; Garrett EN; Patawaran MB; Hollenbach PW; Aukerman SL; Weiner AJ
    Antimicrob Agents Chemother; 2006 Oct; 50(10):3260-8. PubMed ID: 17005803
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potent inhibitors of the hepatitis C virus NS3 protease: design and synthesis of macrocyclic substrate-based beta-strand mimics.
    Goudreau N; Brochu C; Cameron DR; Duceppe JS; Faucher AM; Ferland JM; Grand-Maître C; Poirier M; Simoneau B; Tsantrizos YS
    J Org Chem; 2004 Sep; 69(19):6185-201. PubMed ID: 15357576
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.